Syenza News — health technology assessment, market access and health economics
Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%
Merck and Moderna report a 42% reduction in recurrence or death for intismeran plus KEYTRUDA in resected stage IIB-IV melanoma, with full data at ESMO 2026. #SyenzaNews #melanoma #MarketAccess
Recent Posts
FDA Launches Neuroscience Medical Product Development Program
Oct 23
Clinical AI governance framework guides AI tool evaluation
Oct 23
Palbociclib Maintenance in HER2-Positive Breast Cancer: EMA Withdrawal
Oct 23
Health Economists in Clinical Trials: Why Early Engagement Matters
Oct 22
New Drug Launch Prices Stay High While Patients Wait for Access
Oct 21Syenza's Top Picks
Health Security in Europe: Why Resilience Starts Before a Crisis
Oct 13, 2026
FDA Rare Disease Framework Initiative Would Tailor Review to Small Populations
Oct 15, 2026
Semaglutide for Opioid Use Disorder: $13.3M Trial Planned in Allegheny County
Oct 15, 2026
AI guidance in clinical development: what industry is asking for
Oct 15, 2026
Social prescribing in Portugal: pilots, gaps and the cost of time
Oct 15, 2026
EMA Expert Panel Consultation for Medical Devices Adds an Orphan Pathway
Oct 14, 2026
Latest News
Clinical Practice
CagriSema Weight Loss in Women: Menopause Stages in REDEFINE 1
Two post hoc REDEFINE 1 analyses show CagriSema weight loss in women held across premenopausal, perimenopausal and postmenopausal stages. #SyenzaNews #obesity #MarketAccess
Health Policy Free account
Medicaid Provider Taxes Raise Private Insurance Premiums, ASPE Finds
ASPE finds Medicaid hospital provider taxes raised employer premiums 1.5 to 1.7 percent, and the 2025 WFTC law is projected to cut them further.
Alzheimer's Disease
Biomarker laboratory in Portugal opens at University of Porto
A new biomarker laboratory in Portugal opens on 21 October at the University of Porto, funded with 2.1 million euros from the PRR. #SyenzaNews #biomarkers #precisionmedicine
Clinical Practice
Emvistegrast in ulcerative colitis hits Phase 2 primary endpoint
Gilead’s once-daily oral emvistegrast met the primary endpoint in Phase 2 SWIFT ulcerative colitis data, with 66% clinical response at Week 12 versus 37% on placebo. #SyenzaNews #biotechnology #MarketAccess
Clinical Practice
Jemperli rectal cancer approval may let some patients skip standard treatment
FDA grants accelerated approval for Jemperli in locally advanced rectal cancer, based on interim AZUR-1 results. #SyenzaNews #oncology #MarketAccess
Clinical Practice
Adverse reaction reports in Portugal rise with GLP-1 use
Infarmed has logged 695 suspected adverse reactions to GLP-1 drugs in Portugal since 2024, most linked to Mounjaro.
Clinical Practice
Foundayo Oral GLP-1 Tablet Gets Positive EU Opinion
The EMA’s CHMP has backed Foundayo, a once-daily orforglipron tablet, for weight management and type 2 diabetes.
Clinical Practice Free account
EMA Draft Reflection Paper Sets Rules for Confirmatory Platform Trials
“EMA’s draft reflection paper sets out how confirmatory platform trials should handle controls, randomisation, blinding and multiplicity. Comments are due 31 January 2027. #SyenzaNews #MarketAccess #ClinicalTrials”
Clinical Practice
Reinforcement learning rTMS for depression treatment
Reinforcement learning rTMS for depression: a new npj Digital Medicine study tests protocol recommendations against clinician choices in 1,609 adults.
Clinical Guidelines And Protocols
AI operating room scheduling: LLM agent teams reach feasible plans
How can AI-powered scheduling transform operating room efficiency and deliver major cost savings?
Recent advancements are enabling hospitals to optimize resource allocation, reduce cancellations, and streamline workflows through intelligent automation.
Discover how this technology is reshaping surgical operations and improving financial outcomes.
#SyenzaNews #AIinHealthcare #HealthcareInnovation #ai #DigitalTransformation
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.
